Johnson & Johnson (NYSE:JNJ) CEO William C. Weldon said in an interview that declines in medical spending could be nearing a bottom.The CEO sees signs that a drop in elective procedures including knee and hip replacements is leveling off, and could help boost sales by as much as 2% this year.
